Press Releases

Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer

BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.

Arch Oncology to Present at Upcoming Conferences

BRISBANE, CA and ST. LOUIS, MO, October 26, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings.

Arch Oncology Announces Formation of Scientific Advisory Board

BRISBANE, CA and ST. LOUIS, MO, June 22, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts.

Arch Oncology Appoints Drew Dennison to Board of Directors

BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to Board of Directors.

Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer

BRISBANE, CA and ST. LOUIS, MO, May 22, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer. In this newly-created position, Mr. Christoffersen will lead Arch Oncology’s corporate strategy and other business functions reporting to Julie Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.

Arch Oncology to Present Preclinical Data on Highly-differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019

BRISBANE, CA and ST. LOUIS, MO, March 29, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.

Arch Oncology Raises $50 Million Series B Financing

BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.